| Title | Triple verses Glimepiride plus Metformin therapy on Cardiovascular Risk Biomarkers and Diabetic-Cardiomyopathy in Insulin Resistance Type 2 Diabetes Mellitus Rats. | | Author(s) | Sharma AK, Srinivasan BP | | Institution | Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences & Research. Pushpvihar. Sector-III. New Delhi. Pincode-110017. India. | | Source | Eur J Pharm Sci 2009 Sep 15. | | Abstract | IRtype2DM patients are often treated with a combination of antidiabetic agents. Drugs with different complementary mechanisms of action frequently used in daily clinical practice but glycemic control with monotherapeutic attempts fail in the long run. To date, biomarkers for cardiovascular risk and insulin sensitivity with combination of triple oral hypoglycemic therapies are not fully revelled in view of additional cardiovascular risk reduction. In present study, IRtype2DM induced by administering streptozotocin (90mg/kg,i.p.) in neonatal rat model. IRtype2DM rats were selected by determining FPI[>60pmol/L]; HOMA-IR & Hyperinsulinemic euglycemic clamp technique at six weeks and then treated for eight weeks with (i)Metformin(120mg/kg.o.d.)+Glimepiride (1mg/kg.o.d.) (ii)Metformin(265mg/kg.o.d.)+Rosiglitazone(1mg/kg.o.d.)+Glimepiride (0.7mg/kg.o.d.). At the end cardiovascular risk parameters evaluated by ELISA kits and insulin sensitivity was determined by HOMA-IR. In conclusion, Triple oral hypoglycaemic therapy improves glycemic control, insulin sensitivity, retards diabetic cardiomyopathy and does not increased body weight; decrease more detrimental inflammatory markers, increase interlukin-10 and adiponectin in neonatal streptozotocin induced IRtype2DM Wistar Albino Rats. Triple therapy showed a synergistic effect and was promising in insulin resistance, better in additional cardiovascular risk reduction and those nonresponders to metformin add on glimepiride therapy. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19765654 |
|
